Advancing Medicine. Enhancing Life.      www.acr-research.com

 
 
Current and Future Studies
Participant Feedback
 
 
 
  ACR Utah 801-542-8190
 ACR Idaho 208-377-8653
 

 

Influenza Virus Vaccine Research Study

 

Advanced Clinical Research (ACR) is conducting a clinical study regarding an investigational flu vaccine. During flu season in the United States, more than 200,000 people are admitted to a hospital for complications related to the flu; each year roughly 20,000 Americans die from these complications. Most of these deaths occur in people older than 65 years. (www.medicinenet.com)

Advanced Clinical Research is seeking healthy volunteers 65 years and older who have not received a flu shot within the last 6 months, nor received any other vaccine within the last 4 weeks. Participants must not have a history of allergic reactions to any vaccines or vaccine components.

Patients who qualify for this study will receive study-related evaluations from certified medical professionals, as well as up to $325.00. This study consists of two visits to our ACR site, as well as several phone calls.

This Study is being conducted at our Idaho Facility.

For more information please call toll-free: 1-866-704-5163 or for local calls please call          208-377-8653 ext. 102

You may also complete the form below and we will contact you with more information.

You can also fill out our Contact Form below and we will then follow up with more information.
* Designates required fields
*Point of Interest: 
(to select multiple interest, hold down the "ctrl" key while clicking with the left mouse button)
   
*Last Name:  
   
*First Name:  
   
Middle Initial:  
   
Address Line1:  
   
Address Line2:  
   
*City:  
   
*State:  
   
Zip:  
   
*Day Time Phone:  
   
*Night Time Phone: 
   
Email Address: 
 example (jsmith@aol.com not jsmith@aol or jsmith@)
   
Best Time To Contact You:  
   
Date of Birth: 
   
Gender: FemaleMale
   
Previous Clinical Trials Participant  NoYes
   
How Did You Hear About This Study:  
   
Your Comments: